Pasithea said that its Phase 1 clinical trial of PAS-004 for advanced cancer has been cleared to advance to Cohort 6 (30mg capsule), following a recommendation from the independent Safety Review ...

“We are pleased to have recruited, enrolled and commenced dosing of the initial three subjects in Cohort 6 more rapidly than anticipated and we currently expect to complete enrollment of all ...

From there, 6 companies were chosen to take part in the ... and 2025 is no different. This year’s cohort is tackling key areas such as Circular Economy, Product Development, Personalization ...

In April, the external Safety Review Committee recommended that the company’s Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to Cohort 6, 30mg capsule, without modification.